Go back

European pharma R&D spending ‘increased by €1.8bn’ in 2021

But industry body warns sector “faces real challenges” from austerity and global competition

Europe’s pharmaceutical companies increased their spending on R&D by about €1.8 billion between 2020 and 2021, according to new figures.

The European Federation of Pharmaceutical Industries and Associations estimated that companies in the EU, Norway, Switzerland and UK spent €41.5bn on R&D in 2021 compared with €39.7bn in 2020. In 2010, the figure was €27.9bn, Efpia said.

This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Pivot-RP users can log in and view the article via this link.